Business Wire

51. Eureka Genomics Awarded Multi Year Contract To Assist Military Laboratory With DNA Sequencing
    5/22/2012

    Based on collaborative work done for the past twelve months with the Armed Forces DNA Identification Laboratory (AFDIL), Eureka Genomics has been awarded a multi-year contract with AFDIL to provide forensic service support that should advance efforts to identify unknown remains from the Korean War. 

52. Bristol-Myers Squibb And Gilead Sciences Announce Licensing Agreement for Development And Commercialization Of New Fixed-Dose Combination Pill For People Living With HIV
    10/27/2011
    Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb’s protease inhibitor REYATAZ®(atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.
53. Approval Of US Pilot Clinical Trial To Evaluate AclarusDx™, The Exonhit Investigational Test For Alzheimer’s Disease Diagnosis
    10/27/2011
    Exonhit (Paris:ALEHT) announced today the Institutional Review Board (IRB) approval of Exonhit sponsored pilot clinical trial aimed at evaluating the performance of AclarusDx™, a blood based investigational diagnostic test, in US-based patients suffering from memory impairment and newly referred to a reference Memory Center for Alzheimer’s Disease (AD) diagnostic workup. This study will be conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health.
54. BioVigilant Submits Drug Master Files To U.S. FDA For Instantaneous Microbial Detection Systems
    9/1/2011
    BioVigilant Systems, Inc. (www.biovigilant.com), inventors of Instantaneous Microbial Detection™, announced today it has filed Type V Drug Master Files (DMFs) for its IMD-A® 300 series of rapid biologic detection systems for real-time environmental air monitoring in pharmaceutical manufacturing environments.
55. New Survey Finds Life Sciences Companies Struggling To Accurately Forecast Spending For Clinical Studies
    8/1/2011
    ClearTrial recently announced the results of a new survey of life sciences professionals charged with forecasting and budgeting clinical studies at small, mid-sized, and Top 20 biopharmaceutical and medical device companies.
56. Seattle Genetics Announces Antibody-Drug Conjugate Collaboration With Abbott
    3/22/2011
    Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that it has entered into a collaboration agreement with Abbott (NYSE:ABT) under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.
57. Thermo Fisher Scientific Extends Legacy of Innovation at Pittcon 2011
    3/16/2011
    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, will reinforce its long-term commitment to innovation at Pittcon 2011 by showcasing best-in-class instruments, consumables, software and services that drive advancements in global health, environmental and safety applications.
58. Mirrx Therapeutics A/S Secures Seed Financing For Development Of Novel MicroRNA-Blocking Technology
    2/4/2010
    Mirrx Therapeutics today announced that it has closed on a seed financing round that will enable the company to achieve in vivo proof of concept for its microRNA-blocking “Blockmir” technology, as well as to strengthen its intellectual property portfolio.
59. Pfizer Announces Global Research Network
    11/9/2009
    Pfizer Inc today announced its global research and development network, marking an important step in implementing a new R&D model as part of the integration of Pfizer and Wyeth.
60. Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research
    8/20/2009
    Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc announced today that it has entered into a collaboration with Private Access, the innovator in privacy-enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation.